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Abstract 
The anti-inflammatory agent curcumin can selectively eliminate malignant rather than normal cells. 
The present study examined the effects of curcumin on the Lewis lung carcinoma (LLC) cell line 
and characterized a subpopulation surviving curcumin treatments. Cell density was measured after 
curcumin was applied at concentrations between 10 and 60 μM for 30 hours. Because of the high 
cell loss at 60 μM, this dose was chosen to select for surviving cells that were then used to establish 
a new cell line. The resulting line had approximately 20% slower growth than the original LLC cell 
line and based on ELISA contained less of two markers, NF-κB and ALDH1A, used to identify more 
aggressive cancer cells. We also injected cells from the original and surviving lines subcutaneously 
into syngeneic C57BL/6 mice and monitored tumor development over three weeks and found that 
the curcumin surviving-line remained tumorigenic. Because curcumin has been reported to kill 
cancer cells more effectively when administered with light, we examined this as a possible way of 
enhancing the efficacy of curcumin against LLC cells. When LLC cells were exposed to curcumin 
and light from a fluorescent lamp source, cell loss caused by 20 μM curcumin was enhanced by 
about 50%, supporting a therapeutic use of curcumin in combination with white light. This study is 
the first to characterize a curcumin-surviving subpopulation among lung cancer cells. It shows that 
curcumin at a high concentration either selects for an intrinsically less aggressive cell subpopulation 
or generates these cells. The findings further support a role for curcumin as an adjunct to tradi-
tional chemical or radiation therapy of lung and other cancers. 
Key words: Lewis lung carcinoma, curcumin, cancer stem cell, phototoxicity. 
Introduction 
Curcumin, a yellow-orange dye in the spice 
turmeric, causes selective apoptosis in many cancer 
cell types including those of small-cell lung cancer 
while sparing normal cells (1-4). The therapeutic ef-
fects of curcumin against carcinogensis and progres-
sion of tumor growth depend on its inhibition of 
multiple intracellular signaling molecules, most nota-
bly NF-κB that plays a central role in various re-
sponses leading to host defense and also inflamma-
tion (5-7). Curcumin has been documented in the In-
dian medical system Ayurveda for over 6000 years 
and is still prominent in the diets of Asian countries 
(8). Although orally administered curcumin is re-
markably well tolerated and has been evaluated as a 
supplemental chemotherapeutic drug, its bioavaila-
bility is very poor. Oral administration of curcumin 
has shown no effect on mammary, liver, kidney (9) or 
lung cancers (10). Improvements in bioavailability are 
needed to increase the effectiveness of this promising 
drug, particularly for targets outside the gastrointes-
tinal tract. Alternative therapeutic approaches are to 
administer curcumin either directly to tumors or 
through the circulatory system either alone or in 
combination with more traditional cancer treatments. 
When administered with radiation (11-16) or chemo-
therapy (17-20) curcumin sensitizes the tumor to the 
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treatment and improves outcome (21, 22).  
Many cancers return following chemotherapy 
because of resistant cells. In some cases, resistance has 
been attributed to cancer stem cells (CSCs), a small 
subpopulation of self-renewing cells that are thought 
to be critical for tumor recurrence and progression 
and that can proliferate after chemotherapy and radi-
ation therapy (23, 24). In light of the potential benefits 
of curcumin delivered in combination with standard 
cancer therapies, it will be important to characterize 
cells showing tolerance to curcumin. A few reports 
have identified the properties of curcumin-surviving 
subpopulations of tumors or cancer cell lines (25-28). 
Any examination of curcumin-resistance should con-
sider the possible presence of CSCs. 
In this study, we investigated the effect of cur-
cumin on the Lewis lung carcinoma (LLC) cell line. 
The LLC line is a well-established mouse cancer 
model that is commonly used as a transplantable ma-
lignancy model in syngeneic C57BL/6 mice. We also 
generated and characterized a curcumin-surviving 
LLC sub-population and tested its ability to form tu-
mors in mice. Finally, we used LLC cells to replicate a 
reported synergistic effect of light and curcumin on 
cancer cells as a possible way of increasing the effi-
cacy of curcumin.  
Materials and Methods 
Animals 
A transgenic mPer1::luc mouse line that we used 
previously to produce LLC tumors (29) was bred and 
maintained in the BGSU Animal Care Facility under 
standard conditions of 12 hr light:12 hr dark and fed a 
reduced-fat mouse chow ad libitum. The mice were 
originally produced by Dr. Hajime Tei of Mitsubishi 
Kagaku Institute of Life Sciences, Tokyo through oo-
cyte injection and were on a C57BL/6 background 
(30). Although not utilized in this study, these mice 
contain the firefly luciferase gene luc controlled by the 
promoter of the mPer1 gene, enabling biolumines-
cence imaging of tumor growth (29). The mice re-
ceived humane care in accordance with the BGSU 
Institutional Animal Care and Use Committee 
(IACUC). 
Lewis Lung Carcinoma (LLC) cell line 
The LLC cell line was provided by Dr. Stephen 
Kennel of the University of Tennessee Medical Center, 
Knoxville, TN. The cells were cultured in Dulbecco’s 
modified eagle medium (DMEM, GIBCO, Invitrogen, 
NY), supplemented with penicillin (100 U/ml), 
streptomycin (100 µg/ml) and 5 or 10% fetal bovine 
serum (FBS, Atlanta Biological, Lawrenceville, GA), 
referred to here as complete DMEM. The cultured 
cells were kept in 100-mm tissue culture dishes at 
37°C in a humidified atmosphere containing 5% CO2 
(31). 
Curcumin treatment 
To determine the dose-dependent effect of cur-
cumin on LLC cells, the cultured cells were washed, 
trypsinized, collected, counted using a hemocytome-
ter (Hausser Scientific, PA) and subsequently plated 
in 24-well plates at a density of 5×104 cells/well and 
incubated at 37°C. Curcumin (purity 70%, Sigma) was 
dissolved in DMSO, and diluted in complete DMEM 
to provide a curcumin concentration ranging from 10 
to 60 μM. Twenty-four hours after plating, each of the 
four-well columns was washed with PBS once, and 
each column was exposed to 10, 20, 40 or 60 μM cur-
cumin. Four wells treated with complete DMEM or 
complete DMEM with 0.2% DMSO served as controls. 
After incubation, the cell density was assayed with 
the crystal violet staining method according to a 
standard protocol (32). The resulting absorbance of 
the stained cells was analyzed with ANOVA 
(OriginLab, Northampton, MA). The experiment was 
repeated with 2, 4, 8, 16, 24, or 30 hrs of curcumin 
exposure using a range of curcumin dosages. 
Curcumin-surviving LLC sub-population 
To select for a curcumin-surviving cell subpop-
ulation, LLC cells were plated into three 100-mm cell 
culture plates (106 cells/plate) containing 10 ml com-
plete DMEM and incubated at 37°C. After 24 hours, 
the medium was removed and the cells were incu-
bated in complete DMEM containing 60 μM curcumin 
dissolved in 0.2% DMSO for 30 hrs. After incubation, 
the curcumin-containing medium was removed and 
replaced with complete DMEM to allow cells that 
survived the treatment to grow. After the surviving 
cells formed colonies (normally four weeks after 
treatment), they were passaged three times. The cell 
line that developed was designated the curcu-
min-surviving LLC line. 
Growth Curve 
To determine the rate of growth of both cell lines, 
cultured cells were trypsinized, collected, counted 
and plated in 100-mm culture plates at a density of 106 
cells/plate. The cells were trypsinized, collected, and 
counted at 16, 24, 48, 72 and 96 hours after plating. For 
statistical analysis, three plates of cells were used at 
each time point.  
Enzyme-Linked Immunosorbent Assay 
(ELISA) 
ELISA was performed as described previously 
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(31). Briefly, the original LLC line and the curcu-
min-surviving line were washed with PBS, tryp-
sinized, collected, counted, and plated into 96-well 
plates (5×104 cells/well). After incubation at 37°C for 
24 hrs, the plates were washed with PBS once and the 
cells were fixed with methanol for 10 minutes. The 
plates were then washed with PBS twice and incu-
bated with 100 μl complete DMEM containing rabbit 
polyclonal antibodies (anti-p65, Santa Cruz Biotech-
nology, SC-109, 200 µg/ml and anti-ALDH1A1, Pro-
teintech Group, 15910-1-AP, 133 µg/ml) at 37°C for 
two hours. The antibodies were tested at a range of 
dilutions (1:50, 1:100, 1:200, 1:400). Three replicates of 
each dilution were used for statistical analysis. One 
well with only cells was used as blank for each plate. 
After two hours of incubation at 37°C, the wells were 
washed three times with PBS to remove any unbound 
primary antibody and incubated with 100 μl 
β-galactosidase-conjugated goat anti-rabbit secondary 
antibody (1:500 dilution in complete DMEM) at 37°C 
for another two hrs. After incubation, the wells were 
washed with PBS three times and the cells were in-
cubated with 100 μl substrate solution (1 mg/ml 
P-nitrophenyl β-D-galactopyranoside in phosphate 
buffer, pH 8.0) at 37°C for one hour in darkness. The 
development of a yellow color indicated a positive 
reaction. The intensity of the color was measured with 
a MR-600 microwell plate reader (Dynatech Lab. Inc.) 
at 410 nm wavelength. The resulting absorbance was 
analyzed using ANOVA. 
Tumor injection and histology 
The upper rear leg of the mice was injected 
subcutaneously with 106 LLC cells diluted in PBS. 
Three weeks after the injection, tumors were excised 
from euthanized mice, fixed in Histochoice (Amresco, 
Solon, OH) and embedded in paraffin at 57°C. Sec-
tions (5 to 10-μm thick) were mounted on glass slides, 
dewaxed, rehydrated through a series of ethanol di-
lutions and stained with hematoxylin and eosin for 
histological analysis. 
Curcumin and light treatment 
To investigate the effect of curcumin in combi-
nation with visible light, we plated the LLC cells in 
24-well plates at a density of 5×104 cells/well. After 24 
hours of incubation at 37°C, the cells were exposed to 
10, 20, 40 or 60 μM curcumin. After one-hour incuba-
tion, the cells were irradiated for 5 minutes with flu-
orescent light with an intensity of 120 μEinsteins m-2 
s-1 (measured with Apogee Instrument’s Quantum 
Meter). The light source was a portable fluorescent 
light table containing one 13-watt tube directing light 
upwards through a white plastic diffuser, which was 
placed below two cool white F20T12 fluorescent bulbs 
(1200 lumens, Eco Lux Technology) positioned 90 mm 
above the light table. Each cell culture plate was 
placed at the center of the light table and irradiated 
simultaneously from above and below. While the ex-
perimental plates were exposed to light, the control 
plates (treated with curcumin but not exposed to 
light) were removed from the incubator and kept in 
darkness under the same conditions as the experi-
mental group (at room temperature and in room air). 
After the light treatment, all the plates were returned 
to the 37°C incubator and remained in the curcumin 
medium for a total of 24 hours exposure. The cells 
were then stained with crystal violet and the cell den-
sity was analyzed as described above.  
Results 
The Effect of Curcumin on LLC Cells 
The dose-dependent effect of curcumin on LLC 
cells over a range of exposure times is shown in Fig-
ure 1A. The 2-hr curcumin exposure had a significant 
effect only at 60 μM, whereas the 8-hr and 16-hr 
treatments were able to cause significant reduction of 
cells given the lower concentrations. The effect of 
24-hr exposure was significant at 20-60 μM, and was 
similar to that at 30-hr exposure. The cell density of 
the curcumin-free control plate almost doubled dur-
ing the 30-hr period, while the higher curcumin dos-
ages caused a decline (Fig. 1A). Cells treated with 
DMSO were not significantly different from cells 
given complete medium alone. Cell viability after 
treating LLC cells with 5, 10, 20, and 40 µM curcumin 
for 24 hrs was also evaluated using the MTT assay 
(data not shown). A significant 50% reduction in cell 
staining occurred between 20 and 40 µM (ANOVA, 
F=5.646, p=0.00129). 
Comparing the Curcumin-Surviving and 
Original LLC Cell Lines 
According to the dose-response curves, we chose 
a 30-hr exposure with 60 μM curcumin to select a 
curcumin-surviving sub-population. To assess the 
difference between the curcumin-surviving and orig-
inal LLC lines, we compared growth rate and re-
sponses to curcumin along with expression of NF-κB 
and ALDH1A1, both of which are markers associated 
with aggressive cancer cells such as CSCs. We treated 
the LLC line and the curcumin-surviving line with the 
same curcumin concentrations to establish a second 
set of dose-response curves (Fig. 1B). The curcu-
min-surviving line was slightly less sensitive to cur-
cumin than the original line. 
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Figure 1. Reduction of LLC cell proliferation in response to curcumin exposure. A. Shown is the loss of cells caused by 
varying the curcumin (0-60 µM) and treatment interval (2-30 hrs). Each line represents the effect of one dosage of curcumin 
and each point is the mean absorbance in a crystal violet assay from four wells ± SD. B. Reduction of curcumin-surviving LLC 
cells in response to a second exposure of curcumin (0-60 µM for 30 hrs) compared with the original LLC cell line treated for 
30 hrs. Percent cell loss is the percent decline in absorbance relative to the DMSO control. Each point is mean absorbance 
of four wells ± SD. C. The growth rate of curcumin-surviving and original LLC lines. Cell counts were made at 16, 24, 48, 72 
and 96 hrs after plating. Each point is the mean of the number of cells in three plates ± SD. 
 
Growth rate measurements showed that the 
curcumin-surviving line had an approximately 20% 
slower growth rate than the untreated LLC line (Fig. 
1C). After 96 hrs of culture, the original LLC line had 
approximately 50% more cells than the curcu-
min-surviving line (Fig. 1C). ELISA was performed on 
both lines to determine the expression of NF-κB and 
ALDH1A1. The curcumin-surviving line showed a 
lower amount of ALDH1A1 and NF-κB than the 
original line (Table 1, T-test, p<0.05, using 1:100 anti-
body dilution).  
 
 
Table 1. Evaluation of cancer stem cell markers by ELISA 
Primary 
Antibody 
Dilution 
NF-κB level ALDH1A1 level 
Original 
LLC line 
Curcumin 
treated LLC 
line 
Original 
LLC line 
Curcumin 
treated LLC 
line 
1:100 1.233 ±0.10 1.000 ±0.10 0.354 ±0.006 0.108 ±0.001 
1:200 0.664 ±0.05 0.383 ±0.04 0.123 ±0.04 0.056 ±0.10 
1:400 0.294 ±0.08 0.066 ±0.01 0.0985 ±0.02 0.047 ±0.02 
Shown is the average optical density of three wells at 410 nm ±SD. 
 
 
Comparison of Curcumin-Surviving Line and 
the Original LLC Cell Line in vivo 
Mice that were of the same genetic background 
as the LLC cells were used to compare the tumor-
igenicity of the original LLC line and the curcu-
min-treated cell line. Three mice were injected in the 
upper right leg with 106 cells from the curcu-
min-surviving line at the third passage after treating 
LLC cells with curcumin. Three weeks later, each 
mouse had developed small tumors that were then 
removed by dissection. There was no evidence of 
metastasis in lung, spleen, liver, intestine, heart or 
other tissues examined. Histological sections made 
from the tumors revealed cell types found previously 
in tumors made from the original line (29). For exam-
ple, a compact central area of cancer cells and infil-
trating stromal cells, as described previously, were 
also present in tumors from the surviving-cell line 
(Fig. 2). The only obvious difference was that tumors 
of the surviving cell line appeared to contain more 
closely spaced blood vessels passing through the mass 
of cancer cells (Figure 2A). 
In a second experiment, three mice were injected 
with the surviving line and three were injected with 
the original line. Tumors formed in all mice of both 
groups and, as in the first experiment, there was no 
evidence of metastasis at the macroscopic level. Fur-
thermore, the tumors from the curcumin-surviving 
line appeared to be more heavily vascularized than 
tumors from the original line (Figure 2C). 
The Effect of Curcumin and Light on LLC cells 
It has been shown that curcumin in combination 
with light inhibits the growth of E. coli (33), trans-
formed skin keratinocytes (34) and A-431 tumors in a 
xenograft mouse model (35), thereby providing a 
possible way to increase the effectiveness of curcumin 
by combining it with photodynamic therapy of tu-
mors. We tested whether this effect can also be de-
tected with the LLC cell line. We evaluated whether 
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possible phototoxicity or light-absorption by the 
phenol red of normal cell culture media influences the 
combined curcumin-light effect. LCC cells were 
maintained in phenol red containing medium (com-
plete DMEM) and non-phenol red complete medium. 
Above 10 µM the curcumin treatments in combination 
with light produced a greater cell loss than curcumin 
alone in cells maintained in complete DMEM (Fig. 
3A). Above this same dosage cucumin also reduced 
the LLC cell cultures maintained in phenol red-free 
medium more effectively when combined with light 
exposure (Fig. 3B). 
Light itself also produced a loss of cells when 
delivered without curcumin to LLC cells in either 
medium. This effect was larger in the phenol red-free 
medium (39.23%) than in complete DMEM (19.78%), 
as shown in Fig. 3A, B. When these results were plot-
ted as the percentage of the absorbance in the curcu-
min-free group (Fig. 3C, D), treatments above 10 µM 
produced a substantial effect in the complete medium 
and only a modest effect in the phenol red-free me-
dium. 
 
 
Figure 2. Sections through tumors formed from the cur-
cumin-surviving LLC cell line. A. Shown are LLC cells, with 
blue nuclei, near the boundary of the tumor where it is 
infiltrated with blood cells (small arrow) and numerous 
blood vessels (large arrow). B. Sections also showed infil-
tration of muscle cells into the tumor (arrow). C. A rep-
resentative section from a tumor made from the original 
LLC cell line. The sections were stained with hematoxylin 
and eosin, and the scale bar equals 50 µm. 
 
Discussion 
Among all cancers, lung cancer is considered one 
of the deadliest because of aggressive tumor cell 
growth and lack of adequate therapies. We selected a 
well studied lung cancer cell line to evaluate the use of 
curcumin at concentrations that are known to be cy-
totoxic to many different cancer cells (36). Previously, 
when LLC cells were used in an orthotopic tumor 
model, with the cells implanted in the lungs, curcu-
min administered orally had no effect on tumor 
growth but did minimize metastasis to lymph nodes 
near the lungs (37), suggesting that curcumin or its 
metabolites had some effects despite low bioavaila-
bility following ingestion. 
We determined how LLC cells in vitro respond to 
a range of curcumin dosages applied for different 
durations. It was found that 24 to 30-hr treatments 
reduced the number of cells in a dose-dependent 
manner, which is in agreement with published results 
using other cell lines (1) as well as LLC (37). However, 
a shorter treatment interval (2 or 4 hrs) significantly 
reduced the density of cells only when they were 
treated with the highest curcumin dose (60 µM).  
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Figure 3. Effect of curcumin and visible light on LLC cell survival. LLC cells were pre-incubated with 0-40 μM curcumin for 
one hour and then either irradiated with visible light for 5 min or light protected (dark control). Curcumin was applied for 
a total of 30 hrs. A. Average absorbance following the crystal violet assay. B. Cells were treated as in A but were maintained 
in phenol red-free medium. C & D. Same absorbance data as in A & B replotted as percent of the zero-curcumin result. Each 
point is the mean of four wells ± SD. 
 
 
Because curcumin can alter a variety of molecu-
lar targets within cancer cells, we speculated that the 
cells that survived the treatment might be either a 
subset of the cell line that had greater intrinsic re-
sistance to curcumin or LLC cells that had survived 
because they were modified by curcumin before it 
could exert its lethal effects. Curcumin affects cellular 
pathways that rely on AP-1, HIF-1, AKT, NF-κB, and 
other cell signals (3, 6, 38-45). It has been argued that 
the elevated NFkB activity commonly found in more 
aggressive cancer cells endows them with an-
ti-apoptotic properties but also makes them particu-
larly vulnerable to negative selection by curcumin (5, 
46-48). Any cell alteration that would explain curcu-
min effects in this study would need to be transmis-
sible to daughter cells by either genetic or epigenetic 
changes. 
A third possibility is that the surviving cells were 
not different from other cells and merely escaped 
curcumin by chance. To determine the characteristics 
of the surviving subpopulation, we compared the 
growth rate, tumorigenicity, and the NF-κB and 
ALDH1A1 expression levels of both lines. The sur-
viving population showed a lower level in each of 
these categories, suggesting that there was either se-
lection for a less aggressive line or generation of such 
a line by the curcumin treatment, what we are refer-
ring to as modification. Because the surviving cell line 
was found to be different from the original line, the 
third possibility, which does not infer special charac-
teristics of the survivors, can be rejected.  
Similarly, the curcumin exposure that was ap-
plied to the curcumin-surviving cell line revealed a 
slightly lower sensitivity to curcumin relative to the 
original line, indicating that the procedure may have 
selected for a more resistant subpopulation from 
within the original line or, instead, altered a small 
number of cells during the treatment thereby allowing 
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them to survive. The LD50 for curcumin was increased 
by about 50%. This result has implications for any 
cancer therapy in which cucumin is used as a 
chemotherapeutic agent against cancer cells, rather 
than merely as a dietary supplement intended to serve 
as a cancer preventative. Instead of the typical out-
come observed with other chemotherapeutics, cur-
cumin does not appear to leave behind more aggres-
sive and curcumin-resistant tumor cells that could 
lead to cancer recurrence. 
The outcome of the tumor growth experiment is 
consistent with the apparently slower growth of the 
curcumin-surviving cells in vitro relative to the origi-
nal LLC cells. These cells remained tumorigenic but 
did so less effectively, perhaps because of their slower 
growth rate. Although LLC cells may be representa-
tive of other cancer cell types, these results should be 
confirmed by examining the curcumin-surviving 
progeny of cancer cells derived from distinctly dif-
ferent tissues.  
The results of these experiments are consistent 
with recent reports that indicate a loss of CSCs from 
cancer cell lines in response to a single curcumin 
treatment (49-51). According to the CSC theory, tumor 
recurrence and metastasis are primarily caused by a 
small subpopulation of self-renewing cells that can 
differentiate into other cancer cells. CSCs are consid-
ered to be aggressive and more resistant cells that 
escape from chemotherapy. In contrast, the surviving 
LLC cells had slower replication, slightly greater re-
sistance to curcumin, and lower levels of ALDH1A1 
and NF-κB, which are considered markers of CSCs 
(52-54) and found in more robust cancer cells (55, 56). 
Although we have no direct evidence of CSCs in the 
LLC cell line, the explanation above does agree with 
the results and should be explored further by search-
ing for additional characteristics of CSCs in the cell 
cultures and LLC tumors. 
Studies suggest that direct interactions between 
CSCs and curcumin are credible (25). For example, 
resistance to curcumin in melanoma cells has been 
attributed to high expression of the ATP-binding 
cassette transporter ABCA1 leading to efflux of cur-
cumin from the cells (57). ABC transporters may pro-
vide CSCs with multidrug resistance that allows them 
to survive chemotherapy (58). Exclusion of fluores-
cent dyes by the elevated activity of ABC transporters 
can be used to identify putative CSCs and non-cancer 
stem cells (24, 59) and should be applied to LLC cells. 
One study does, however, suggest that the LLC 
line lacks a distinct CSC subpopulation and argues 
instead that nearly all of the cells are tumorigenic (60). 
Nevertheless, the specific proportion of CSC cells 
found in cancer cell lines is apparently quite variable 
between lines and somewhat plastic within lines as it 
changes with factors in the media that have yet to be 
fully characterized (61). Results of the present study 
seem to be best explained by curcumin either pro-
ducing a sustained suppression of the CSC subpopu-
lation or tempering the aggressive tumorigenicity and 
growth that is perhaps characteristic of all cells within 
the LLC line. In either case, curcurmin may have 
caused an increased differentiation of the cells away 
from the normal LLC phenotype as has been de-
scribed for its effects on stem cells (51). 
We favor an explanation in which CSC proper-
ties are diminished by curcumin because this clarifies 
why the curcumin-surviving cell line appears less 
tumorigenic, and less sensitive to curcumin, and also 
expresses less of the markers of aggressive cells that 
are also attributes of CSCs. CSCs are hypothesized to 
divide slowly in tumors, thereby providing one ex-
planation for how they escape the effects of an-
ti-mitotic chemotherapy (62), but it is not clear 
whether they divide faster in vitro than non-CSCs. 
One interpretation of the slower growth of the cur-
cumin-surviving line is that it contains fewer aggres-
sively dividing cells which may or may not be CSCs. If 
curcumin is acting on CSCs within the LLC line, then 
this explanation requires that curcumin acts unlike the 
many other chemicals that are toxic to cancer cells, 
because CSCs are considered resistant to standard 
chemotherapies, whereas these cells appear to be se-
lectively targeted by curcumin. This targeting would 
be either elimination or modification of the CSCs. 
Treatments employing curcumin or curcumin deriva-
tives could be particularly effective supplements for 
conventional cancer treatments if they eliminate, dif-
ferentiate, or weaken CSCs. 
In support of this argument, a cell subpopulation 
with stem cell properties in the C6 rat glioma cell line 
is selectively eliminated by curcumin treatment (25), 
and curcumin encapsulated in nanoparticles may be 
effective at inhibiting stem cells implicated in brain 
tumor growth (50). Evidence also indicates that cur-
cumin promotes brain neurogenesis from stem cells 
by inhibiting histone acetylation, further promoting 
its use against gliomas (27) and possibly lung cancer. 
Cancer stem cell characteristics are diminished in a 
breast cancer cell line given curcumin (26). Further-
more, colon cancer cells isolated according to the 
stem-cell marker aldehyde dehydrogenase are sup-
pressed by a cucumin analog (63). Colon cancer stem 
cells appear to be effectively killed by treatments of 
curcumin combined with conventional chemothera-
peutic agents such as 5-fluorouracil or cisplatin (28, 
49). 
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Although curcumin has cancer prevention po-
tential and therapeutic value, its poor absorption and 
high rate of degradation could limit clinical applica-
tions (51, 64). Therefore, we conducted the light ex-
periment to evaluate how to enhance the effectiveness 
of curcumin. The results showed that visible light and 
curcumin reduced the LLC cell population by about 
half at a concentration as low as 20 µM, which is con-
sistent with previous findings (34), although those 
studies found significant effects at lower curcumin 
concentrations than we did. Because the reduction in 
LLC cells was smaller when phenol red was not pre-
sent, we suggest that some of the phototoxicity was 
caused by light interacting with this dye rather than 
just with curcumin or from an additional effect of 
phenol red. Phenol red has been described as estro-
genic in some cell lines (65). How this effect might 
produce greater phototoxicity in LLC cells is unclear.  
Nevertheless, our results suggest that the pho-
totoxicity from curcumin in other cancer cell lines 
may also be due in part to light interacting with phe-
nol red. We also detected cell loss in response to light 
in phenol red-free medium without curcumin present, 
and this effect was smaller in the complete medium, 
suggesting that some of the effective wavelengths of 
light were absorbed by the complete medium. Be-
cause of this cell death caused by light alone, sub-
stantially more intense light treatments were not 
tested. The light intensity used here was roughly 
comparable to the intensity of sunlight on an overcast 
day. 
The outcome of photodynamic therapy has been 
positive for some types of lung cancer (66). Our re-
sults suggest that curcumin delivered directly to tu-
mors or through the circulation could be made more 
effective when combined with existing photodynamic 
equipment capable of producing suitable light in the 
visible spectrum. According to curcumin’s peak ab-
sorption in the blue range this wavelength would be 
expected to be most effective. Curcumin is degraded 
in the intestinal lumen before absorption, in the liver, 
and elsewhere (67). A curcumin treatment used along 
with some form of light therapy might offset losses of 
curcumin in the body by making lower doses more 
biologically active. 
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